Findings

What do systematic reviews say?

58 questions · 59 findings · 4 reviews · Gynaecology and Fertility

Sort:Best matchNewest Highest certainty Download CSV

No studies found 17 · 28.8%GRADE not reported 1 · 1.7%Very low 16 · 27.1%Low 22 · 37.3%Moderate 3 · 5.1%High 0 · 0%

GnRH‐a + raloxifene vs GnRH‐a ± placebo

Uterine size (cm3) ‐ · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 91 participants
Low

GnRH‐a + raloxifene vs GnRH‐a ± placebo

Uterine bleeding · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 91 participants
Low

GnRH‐a + raloxifene vs GnRH‐a ± placebo

Severity of vasomotor symptoms · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 91 participants
Low

GnRH‐a + raloxifene vs GnRH‐a ± placebo

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Quality of life · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Bone density (SMD) ‐ · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 95 participants
Low

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Uterine size (cm3) ‐ · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Uterine bleeding · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Severity of vasomotor symptoms · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

GnRH‐a + ipriflavone showed no clear difference in rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
RR 0.67 [0.44, 1.02]
1 study · 95 participants
Low

GnRH‐a + conjugated estrogens vs GnRH‐a ± placebo

Reduction in uterine size · women with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Quality of life · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Bone density (SMD) ‐ · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Low

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Uterine size (cm3) ‐ · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 32 participants
Low

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Uterine bleeding · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Severity of vasomotor symptoms · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

GnRH‐a + medroxyprogesterone acetate may leads to lower rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
RR 0.13 [0.02, 0.84]
1 study · 16 participants
Low

GnRHa treatment vs no treatment

No studies included for any outcomes · women with endometriosis

The review found no eligible studies for this question.

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRHa treatment vs danazol

Relief of pain · patients with pain associated with endometriosis

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

GnRHa treatment vs danazol

Relief of overall pain ‐ reported as pelvic pain ‐ 3 months · patients with pain associated with endometriosis

1 finding from 1 review

Gonadotropin‐releasing hormone analogues for endometriosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low